Edwards Lifesciences Corp 4
4 · Edwards Lifesciences Corp · Filed Apr 28, 2017
Insider Transaction Report
Form 4
Verguet Patrick B
CVP, Europe
Transactions
- Sale
Common Stock
2017-04-27$108.36/sh−6,705$726,523→ 146,432.15 total - Exercise/Conversion
Employee Stock Option (Right to Acquire)
2017-04-27−24,000→ 0 totalExercise: $25.48From: 2011-05-13Exp: 2017-05-12→ Common Stock (24,000 underlying) - Exercise/Conversion
Common Stock
2017-04-27$25.48/sh+24,000$611,520→ 153,137.15 total - Sale
Common Stock
2017-04-27$109.33/sh−9,659$1,055,988→ 129,137.15 total - Sale
Common Stock
2017-04-27$110.08/sh−7,636$840,580→ 138,796.15 total
Footnotes (6)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 10, 2017.
- [F2]This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator.
- [F3]This transaction was executed in multiple trades at prices ranging from $107.83 to $108.82. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $109.89 to $110.48. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F5]This transaction was executed in multiple trades at prices ranging from $108.83 to $109.82. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F6]This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.